



Description générale

Doxorubicin is an anthracycline antineoplastic agent, used in treatment protocols for various cancers.

INN	Doxorubicin
Codes ATC	L01DB01 L01AA01
Type de médicament	Chemical agent
Historique des statuts LME	<p>Ajouté pour la première fois en 1977 (TRS 615) pour Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Ajouté en 2011 (TRS 965) pour Lymphoid leukaemia, not elsewhere classified</p> <p>Ajouté en 2011 (TRS 965) pour Burkitt lymphoma including Burkitt leukaemia</p> <p>Ajouté en 2015 (TRS 994) pour Follicular lymphoma</p> <p>Ajouté en 2015 (TRS 994) pour Malignant neoplasms of breast</p> <p>Ajouté en 2015 (TRS 994) pour Hodgkin lymphoma</p> <p>Ajouté en 2015 (TRS 994) pour Kaposi sarcoma of unspecified primary site</p> <p>Ajouté en 2015 (TRS 994) pour Diffuse large B-cell lymphomas</p> <p>Ajouté en 2015 (TRS 994) pour Malignant neoplasms of kidney, except renal pelvis</p> <p>Ajouté en 2015 (TRS 994) pour Ewing sarcoma of bone and articular cartilage of unspecified sites</p> <p>Ajouté en 2015 (TRS 994) pour Osteosarcoma of bone and articular cartilage of unspecified sites</p> <p>Retiré en 2015 (TRS 994) pour Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Ajouté en 2015 (TRS 994) pour Other specified malignant neoplasms of breast</p> <p>Ajouté en 2019 (TRS 1021) pour Plasma cell myeloma</p> <p>Demande refusée en 2021 (TRS 1035) pour Rhabdomyosarcoma primary site</p> <p>Ajouté en 2023 (TRS 1049) pour Anaplastic large cell lymphoma, ALK-positive</p> <p>Ajouté en 2023 (TRS 1049) pour Anaplastic large cell lymphoma, ALK-negative</p>
Wikipédia	Doxorubicin 
DrugBank	Doxorubicin 

Recommandations

Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)

Indications

Diffuse large B-cell lymphomas

Malignant neoplasms of breast

Hodgkin lymphoma

Kaposi sarcoma of unspecified primary site

Follicular lymphoma

Unspecified malignant neoplasms of ill-defined or unspecified sites

Osteosarcoma of bone and articular cartilage of unspecified sites

Ewing sarcoma of bone and articular cartilage of unspecified sites

Lymphoid leukaemia, not elsewhere classified

Malignant neoplasms of kidney, except renal pelvis

Burkitt lymphoma including Burkitt leukaemia

Other specified malignant neoplasms of breast

Plasma cell myeloma

Rhabdomyosarcoma primary site

Anaplastic large cell lymphoma, ALK-positive

Anaplastic large cell lymphoma, ALK-negative

